Replies to post #13957 on OncoSec Medical Inc (ONCSQ)

[lasers]

Yes precisely and that is why the full impact of the Melanoma Phase2A TLD must wait until after the Jun 2 presentation. The average person is only going to understand the response statistics. However the attending Pharma Reps will understand better the exact details that Dr. Daud is presenting and will be able to conclude that $ONCS ImmunoPulse therapy with IL-12 now makes sense and is NOT an aberration of events but rather a highly predictable therapy each and every application.